On this week’s episode, we chat with Gabriel Levin, gynecologic oncologist at the McGill University Health Centre, and director of oncology at CureLab Oncology Inc., about elanagen, a promising therapeutic advance for women with platinum-resistant ovarian cancer; Eden Ben, CEO of Amorphical, about nano-amorphous mineral therapeutics inspired by blue crayfish; and Hans Schambye, CEO of BOOST Pharma, a company making progress in the battle with brittle bone disease.
Times:
03:36 Amorphical
26:26 CureLab Oncology
43:31 BOOST Pharma
CureLab Oncology
CureLab Oncology Inc. is a clinical-stage biotechnology company headquartered in the greater Boston area. The company is focused on developing safer, more effective treatments for solid tumours and inflammatory conditions.
CureLab's lead programme, Elenagen, is an investigational DNA therapy consisting of a plasmid encoding the human protein p62/SQSTM1. In clinical studies conducted outside the US, Elenagen demonstrated a strong safety profile and statistically significant clinical benefit when combined with chemotherapy, along with evidence of immune activation and mitigation of chronic inflammation.
Amorphical
Amorphical is a biopharma company advancing a novel class of nano-amorphous mineral therapeutics, inspired by the blue crayfish.
